ISIsabela Busto Silva

Isabela Busto Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isabela Busto Silva has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Luiz Augusto Fanhani Cracco

    Pontifical Catholic University of Paraná (PUCPR), Curitiba, Brazil

    3 shared publications
  • Caio Pereira Mueller

    Universidade Federal do Paraná Curitiba PR Brasil Universidade Federal do Paraná, Curitiba, PR, Brasil

    2 shared publications
  • Cléo Otaviano Mesa Júnior

    Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil

    2 shared publications
  • Fabíola Yukiko Miasaki

    Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil

    2 shared publications
  • Gisah Amaral de Carvalho

    Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil

    2 shared publications
  • Hans Graf

    Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil

    2 shared publications

Latest Publications

  • Remission and relapse rates in Graves’ disease treated with methimazole: a 20-year retrospective cohort study

    by Isabela Busto Silva, Gisah Amaral de Carvalho, Fabíola Yukiko Miasaki, João Pedro Ignotti de Almeida, Matheus Pessini Sousa, Caio Pereira Mueller, Hans Graf, Mariana Driesel Bertolin, Cléo Otaviano Mesa Júnior

    Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate [...] ABSTRACT Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate

  • Open Access

    The decline of iodine therapy in the treatment of Graves’ disease in a hospital center: a 20-year analysis

    by Isabela Busto Silva, Gisah Amaral de Carvalho, Fabíola Yukiko Miasaki, João Pedro Ignotti de Almeida, Matheus Pessini Sousa, Caio Pereira Mueller, Hans Graf, Mariana Driesel Bertolin, Cléo Otaviano Mesa Júnior

    Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group [...] ABSTRACT Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group

    • 3 December 2025
      • Vol. 70  (Spe1) , e250075
    Open Access

    The impact of thyroid disorders on the gut microbiome: emerging mechanisms and clinical relevance.

    by Isabela Busto Silva, Manuel Puig-Domingo

    The thyroid-gut axis represents a dynamic interaction between the intestinal microbiota and thyroid function, with growing evidence linking gut dysbiosis to thyroid diseases. The gut microbiome, comprising over 100 trillion microorganisms, influences immune modulation, iodine metabolism, and thyroid hormone regulation. Short-chain fatty acids, produced by beneficial gut bacteria, support immune homeostasis and thyroid function, while pathogenic bacteria and lipopolysaccharides trigger inflammatory pathways that impair thyroid activity. Alterations in gut microbiota composition have been associated with autoimmune thyroid diseases, including Hashimoto's thyroiditis and Graves' disease. Dysbiosis increases intestinal permeability, antigen exposure, and immune activation, exacerbating thyroid autoimmunity. A reduction in short-chain fatty acids-producing bacteria weakens immune tolerance, promoting inflammatory cytokine release and autoantibody production. Recent studies highlight microbial metabolites such as tryptophan derivatives and their role in immune regulation. Gut dysbiosis is also implicated in thyroid nodules and cancer. Decreased butyrate-producing bacteria and increased inflammatory bacterial taxa have been observed in thyroid malignancies. Microbiota influence iodine and selenium bioavailability, essential for thyroid hormone synthesis, and modulate sodium-iodide symporter expression, affecting thyroid cancer response to radioactive iodine therapy. Microbiome-targeted interventions, including probiotics, prebiotics, dietary modifications, and fecal microbiota transplantation, may restore microbial balance, enhance immune regulation, and improve thyroid treatments. This review synthesizes our current understanding of the thyroid-gut axis, indicating that the intestinal microbiota and its metabolites may act directly or indirectly on the thyroid gland, highlighting potential clinical implications and paving the way for therapeutic strategies targeting the intestinal microbiota.


  • Open Access

    Association between inpatient glycemic variability and COVID-19 mortality: a prospective study

    by Salma Ali El Chab Parolin, Rebecca Benicio Stocco, Julia Do Carmo Kneipp Lopes, Marcos Roberto Curcio Pereira, Milena Massae Yamashita, Maria Eduarda Domareski Goulart, Henrique Demeneck, Marcia Olandoski, Larissa Hermann de Souza Nunes, Victor Keniche Morisawa, et al.

    Background: This study aimed to determine the association between glycemic variability (GV) and mortality in hospitalized patients with coronavirus disease 2019 (COVID-19). Methods: We prospectively analyzed data from inpatients (> 18 years old) with RT-PCR confirmed COVID-19 admitted between March 2020 and July 2021. All patients were hospitalized for more than 48 h and had at least six point-of-care capillary glucose tests obtained three times daily in the pre-prandial period during hospitalization. GV was measured using the glucose standard deviation (SD) and coefficient of variation (CV). ROC curve was adjusted to determine the SD and CV cutoff values associated with mortality (44.7 mg/dL and 27.5%, respectively); values above these were considered indicative of high GV. Logistic regression models were fitted to explore the association between GV and mortality in patients with and without diabetes. Results: A total of 628 patients were stratified into SD < 44.7 mg/dL (n = 357) versus ≥ 44.7 mg/dL (n = 271) and CV < 27.5% (n = 318) versus ≥ 27.5% (n = 310) groups. After controlling for age, sex, presence of diabetes mellitus (DM) and cardiovascular disease, we found a significant association between high GV and mortality (odds ratio 2.99 [1.88–4.77] for SD and 2.43 [1.54–3.85] for CV; p values < 0.001). The mortality rate was higher with SD ≥ 44.7 mg/dL and CV ≥ 27.5% compared to that with SD < 44.7 mg/dL and CV < 27.5%, regardless of DM (p < 0.001 for all). Conclusion: High glycemic variability was independently associated with mortality in patients with and without DM, who were hospitalized with COVID-19.


  • Open Access

    Immune Response Gaps Linked to SARS-CoV-2 Infection: Cellular Exhaustion, Senescence, or Both?

    by Leonardo Vinicius Barbosa, Daniele Margarita Marani Prá, Seigo Nagashima, Marcos Roberto Curcio Pereira, Rebecca Benicio Stocco, Francys de Luca Fernandes da Silva, Milena Rueda Cruz, Djessyka Dallagassa, Thiago João Stupak, George Willian Xavier da Rosa Götz, et al.

    The COVID-19 pandemic, promoted by the SARS-CoV-2 respiratory virus, has resulted in widespread global morbidity and mortality. The immune response against this pathogen has shown a thin line between protective effects and pathological reactions resulting from the massive release of cytokines and poor viral clearance. The latter is possibly caused by exhaustion, senescence, or both of TCD8+ cells and reduced activity of natural killer (NK) cells. The imbalance between innate and adaptive responses during the early stages of infection caused by SARS-CoV-2 contributes to the ineffective control of viral spread. The present study evaluated the tissue immunoexpression of the tissue biomarkers (Arginase-1, CCR4, CD3, CD4, CD8, CD20, CD57, CD68, CD138, IL-4, INF-α, INF-γ, iNOS, PD-1, Perforin and Sphingosine-1) to understand the cellular immune response triggered in patients who died of COVID-19. We evaluated twenty-four paraffin-embedded lung tissue samples from patients who died of COVID-19 (COVID-19 group) and compared them with ten lung tissue samples from patients who died of H1N1pdm09 (H1N1 group) with the immunohistochemical markers mentioned above. In addition, polymorphisms in the Perforin gene were genotyped through Real-Time PCR. Significantly increased tissue immunoexpression of Arginase, CD4, CD68, CD138, Perforin, Sphingosine-1, and IL-4 markers were observed in the COVID-19 group. A significantly lower immunoexpression of CD8 and CD57 was also found in this group. It is suggested that patients who died from COVID-19 had a poor cellular response concerning viral clearance and adaptive response going through tissue repair.


  • Open Access

    Amiloidose fora de centros especializados: a identificação é possível?

    by Luiz Augusto Fanhani Cracco, Isabela Busto Silva, Edson Marcos Campos Lessa Junior, Gustavo Lenci Marques, Giovanna Vinholi

    Objetivos: relatar a experiência do diagnóstico de amiloidose, uma doença de frequência incomum nos hospitais gerais, através de técnicas simples e acessíveis de coloração histológica. Metodologia: relatamos o caso de um paciente de 57 anos de idade, que foi admitido no departamento de emergência devido a complicações de hipertensão arterial sistêmica com evidências de doença de depósito, submetido à biópsia renal. Resultados: a análise histológica confirmou a presença de depósitos amiloides renais através da coloração cristal de violeta. Conclusões: técnicas histopatológicas simples e acessíveis são métodos viáveis para auxiliar no diagnóstico de amiloidose, uma doença de depósito infrequente em centros não especializados.